Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma.
OBJECTIVE
We sought to assess the efficacy of combined therapy after superselective arterial cisplatin infusion (SACI) therapy to treat the maxillary squamous cell carcinoma.


METHODS
We conducted a retrospective chart review of 50 patients. After completion of two courses of SACI, 25 of the patients were successively treated by concurrent SACI and radiotherapy (AR), while the other 25 patients were treated by surgery with postoperative radiotherapy (ASR).


RESULTS
Patients with surgery (ASR) had an 88% local control rate with 75% disease-free survival rate at 60 months by Kaplan-Meier analysis, compared with 62% disease-free survival rate for patients with AR treatment. A particularly good outcome was obtained in T4 cases of the ASR group (n=8) whose 5-year survival rate was 87% and local control rate was 100%.


CONCLUSIONS
Combined SACI therapy is very effective for the treatment of maxillary squamous cell carcinomas and contributes to the improving prognoses of patients and organ preservation rates.
Shiga
Kiyoto
K
Department of Otolaryngology-Head and Neck Surgery, Tohoku University Hospital, Sendai, Japan. kshiga@orl.med.tohoku.ac.jp
Yokoyama
Junkichi
J
Hashimoto
Sho
S
Saijo
Shigeru
S
Tateda
Masaru
M
Ogawa
Takenori
T
Watanabe
Mika
M
Kobayashi
Toshimitsu
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods*; D008297:Male; D008437:Maxilla / Q000473:pathology / Q000601:surgery; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D009367:Neoplasm Staging; D017233:Orbit Evisceration
D000970:Antineoplastic Agents; D002945:Cisplatin